Targeted Delivery of Talazoparib to Treat Non-Small Cell Lung Cancer
Mentor: Robert Cormack, Ph.D. (Dana Farber Cancer Institute)
221,200 cases of lung cancer (LC) are diagnosed annually, and more than 158,040 patients die from LC. Non-Small Cell Lung Cancer (NSCLC) accounts for 85% of the diagnosed cases, and is relatively insensitive to chemotherapy and radiation therapy.Creating novel therapies that are personalized to the patients and are highly tumor specific with minimal systemic toxicity are desperately needed for this terrible disease. Combination chemotherapy and chemoradiation therapy with NanoTalazoparib In vivo studies of therapeutic efficacy and toxicity will be carried out in A549 and Calu6 cells induced xenograft mouse models, with combination chemotherapy , radiosensitization, and combination triple chemoradiation therapy,in GEMM. If successful NanoTalazoparib will have enhanced synergistic radiosensitization, enabling lower radiation doses than the standard of care, with minimum systemic toxicities associated with non-specific accumulation of the drug.
Figure 2a: Schematic of proposed nanoplatforms for NanoTalazoparib Source: